美国兽医诊断实验室对伴侣动物碳青霉烯耐药菌检测能力调查
2020年对美国42州74家兽医诊断实验室开展调查,23家(31%)来自22州回复。96%(22/23)在初级药敏 panel 中包含至少一种碳青霉烯,约39%(9/23)开展表型碳青霉烯酶检测或碳青霉烯酶基因分子鉴定,35%(8/23)表示检出碳青霉烯耐药菌会通知公共卫生部门,81%(17/21)不了解报告强制要求。
要点
- 多数兽医诊断实验室已检测碳青霉烯耐药,但机制检测能力不足
- 仅约三分之一实验室能开展碳青霉烯酶表型或分子检测
- 多数实验室不了解碳青霉烯耐药菌的公共卫生报告要求
核心结论
- 几乎所有受调查兽医诊断实验室均检测碳青霉烯耐药,但具备机制检测能力或了解公共卫生报告要求者较少。
- 弥补这些差距对监测兽医领域碳青霉烯耐药菌发生率与趋势、防止传播及实施 One Health 应对至关重要。
研究设计与样本
- 2020年对美国42州74家兽医诊断实验室开展调查,23家(31%)来自22州回复。
- 调查对象为从伴侣动物分离菌株中检测碳青霉烯耐药的能力与实践。
主要发现
- 22/23(96%)实验室在初级药敏检测 panel 中包含至少一种碳青霉烯。
- 9/23(39%)实验室开展表型碳青霉烯酶产生检测或碳青霉烯酶基因分子鉴定。
- 8/23(35%)实验室分布在8州,表示检出碳青霉烯耐药菌会通知公共卫生部门。
- 17/21(81%)实验室不了解碳青霉烯耐药菌报告强制要求。
- 部分实验室对已知强制要求是否涵盖兽医来源碳青霉烯耐药菌表示不确定。
临床怎么用
- 兽医诊断实验室应加强碳青霉烯酶机制检测能力建设。
- 应提高实验室对碳青霉烯耐药菌公共卫生报告要求的知晓度。
- 公共卫生与兽医医学需加强协作沟通,以支持感染控制与公共卫生应对。
局限性
- 调查在42州74家兽医诊断实验室中进行,仅23家(31%)回复,应答率有限。
- 摘要未报告调查问卷细节、实验室类型分布及无应答偏倚评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Carbapenems are antimicrobial drugs reserved for the treatment of severe multidrug-resistant Gram-negative bacterial infections. Carbapenem-resistant organisms (CROs) are an urgent public health threat and have been made reportable to public health authorities in many jurisdictions. Recent reports of CROs in companion animals and veterinary settings suggest that CROs are a One Health problem. However, standard practices of U.S. veterinary diagnostic laboratories (VDLs) to detect CROs are unknown. We assessed the capacity of VDLs to characterize carbapenem resistance in isolates from companion animals. Among 74 VDLs surveyed in 42 states, 23 laboratories (31%) from 22 states responded. Most (22/23, 96%) included ≥1 carbapenem on their primary antimicrobial susceptibility testing panel, and approximately one-third (9/23, 39%) performed phenotypic carbapenemase production testing or molecular identification of carbapenemase genes. Overall, 35% (8/23) of VDLs across eight states reported they would notify public health if a CRO was detected. Most (17/21, 81%) VDLs were not aware of CRO reporting mandates, and some expressed uncertainty about whether the scope of known mandates included CROs from veterinary sources. Although nearly all surveyed VDLs tested for carbapenem resistance, fewer had the capacity for mechanism testing or awareness of public health reporting requirements. Addressing these gaps is critical to monitoring CRO incidence and trends in veterinary medicine, preventing spread in veterinary settings, and mounting an effective One Health response. Improved collaboration and communication between public health and veterinary medicine is critical to inform infection control practices in veterinary settings and conduct a public health response when resistant isolates are detected.
引用
- Waltenburg MA, Shugart A, Loy JD, et al. A Survey of Current Activities and Technologies Used to Detect Carbapenem Resistance in Bacteria Isolated from Companion Animals at Veterinary Diagnostic Laboratories-United States, 2020. J Clin Microbiol. 2022. PMID: 34985981. doi:10.1128/JCM.02154-21
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。